experienced

Tracking Cancer Diagnostic and Therapeutic Stocks

The list shows only a relative handful of cancer related r&d firms and gives a somewhat distorted picture. Many firms in the list are in financial trouble, making it unlikely that common shareholders will receive a return commensurate with risks. No timetables are given for approval, other than the test phase for certain compounds. There is not enough material here to make a well formed decision.